FDA guidance aims to help sponsors salvage trials disrupted by COVID-19

As COVID-19 safety concerns and social distancing measures continue to disrupt clinical trials around the U.S., FDA has released guidance to help investigators adapt the design and analysis of affected studies.

By the end of April, BioCentury found that 110 ongoing studies

Read the full 417 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers